Ribociclib-d8
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Ribociclib-d8
Description :
Ribociclib-d8 is the deuterium labeled Ribociclib[1]. Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[2].Product Name Alternative :
LEE011-d8UNSPSC :
12352005Hazard Statement :
H301, H315, H319, H372, H400Target :
CDKType :
Isotope-Labeled CompoundsRelated Pathways :
Cell Cycle/DNA DamageApplications :
Cancer-Kinase/proteaseField of Research :
CancerPurity :
99.23Solubility :
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)Smiles :
CN(C)C(C(N(C1CCCC1)C2=N3)=CC2=CN=C3NC4=CC=C(N5C([2H])([2H])C([2H])([2H])NC([2H])([2H])C5([2H])[2H])C=N4)=OMolecular Formula :
C23H22D8N8OMolecular Weight :
442.59Precautions :
H301, H315, H319, H372, H400References & Citations :
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21 (13) :2905-10.|[3]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 1519 (22) :6173-82.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Isotope-Labeled CompoundsClinical Information :
No Development ReportedCAS Number :
[2167898-24-8]

